NEW STUDY!!!! ACUTE KIDNEY INJURY AND CHRONIC KIDNEY DISEASE ARE LINKED
WASHINGTON (July 3, 2014) — For more than 40 years, physicians have treated diminished kidney function as two distinct syndromes: acute kidney injury (AKI) and chronic kidney disease (CKD). However, recent epidemiologic and mechanistic studies suggest the two syndromes are not distinct entities, but interconnected. Published today in The New England Journal of Medicine, George Washington University (GW) researchers call for greater follow-up care of patients with AKI, who often present with CKD later in life, and vice versa.
"Our teaching has been wrong and the approach to the patient with decreased renal function has been too limited. Every doctor who sees patients with CKD should think about AKI and every doctor who sees a patient with AKI, should think about CKD as a possible sequel of AKI," said Paul Kimmel, M.D., clinical professor of medicine at the GW School of Medicine and Health Sciences (SMHS). AKI, previously called acute renal failure, is often the result of crush injury, a side effect of drugs, or severe infection, and defined as a sudden increase in the serum creatinine concentration and decreased urine output. After recovery, patients receive little to no follow-up care by nephrologists. CKD often lasts a long time, changes slowly, and culminates in dialysis or renal transplantation.
In the article, Kimmel and his co-author, Lakhmir Chawla, M.D., associate professor of anesthesiology and critical care medicine at SMHS and physician at the VA Medical Center, outline several findings suggesting that AKI not only is directly linked to the progression of CKD, but can actually cause CKD. Conversely, the presence of CKD is an important risk factor for the development of AKI. Both AKI and CKD have bad outcomes — most particularly, cardiovascular disease.
FDA Approves First-of-Kind Kidney Disease Test in 62 Days
Posted in Regulatory and Compliance by Jamie Hartford on July 1, 2014
It's the first test that can help determine if membranous glomerulonephritis is due to the body’s rejection of its own kidney tissue or another cause, like an infection.
FDA has approved in 62 days a EuroImmun de novo petition to allow marketing of its Anti-PLA2R IFA blood test, the first test that can help determine if a specific type of kidney disease is due to the body’s rejection of its own kidney tissue or another cause, like an infection.
Membranous glomerulonephritis (MGN) is a chronic kidney disease that causes damage to the cluster of blood vessels in the kidney that filter blood and begin the process to remove waste and excess fluid from the blood.